ClinicalTrials.gg
Not yet recruitingNCT07612657TRANSCENDUpdated May 29, 2026

A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations

A Phase 3 interventional study of VI-0106 and Placebo in Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) and Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), sponsored by VIVUS LLC. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by VIVUS LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized background PAH therapy. Participants will be randomly assigned with equal chance to receive either VI-0106 or placebo in a double-blind fashion to assess whether VI-0106 improves outcomes in this population.

02

Conditions studied

  • Pulmonary Arterial Hypertension
  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
  • Pulmonary Arterial Hypertension PAH
  • Pulmonary Arterial Hypertension WHO Group I

Keywords

  • PAH
  • Pulmonary Arterial Hypertension
03

In context

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

This study's planned enrollment of 300 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

VIVUS LLC is the lead sponsor of 43 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • WHO Group 1 PH: Pulmonary Arterial Hypertension;
  • WHO functional class II - IV despite optimized treatment with one or more modalities. Treatments for PAH must be stable for at least 3 months at the time of screening;
  • Right heart catheterization (RHC) at screening (or within 3 months prior to screening);
  • Screening 6MWD >75 meters to ≤450 meters.

Exclusion criteria

Exclusion Criteria:

  • PAH due to pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis
  • Chronic thromboembolic or portopulmonary hypertension
  • Total Lung Capacity (TLC) \<60% predicted;
  • /FVC \<70% predicted or FEV1 \<60% predicted;
  • Evidence of left-sided heart disease;
  • Inability to safely attempt completion of the 6MWD;
  • \<6 months;
  • \<30 mL/min/1.73 m2 (CKD-EPI equation);
  • Moderate to severe hepatic dysfunction ( score >10);
  • Serum potassium >5.1 mEq/L;
  • Use of experimental PAH treatments within the past 3 months;
  • Active infection requiring antibiotic, antifungal, or antiviral therapies;
  • Current systemic treatment with cyclosporine;
  • Known allergy or to tacrolimus;
  • Significant psychiatric, addictive, or other disorder that compromises the subject's ability to provide , follow study protocol, or adhere to study treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    VI-0106

    Extended-release tacrolimus dosages of 1.25 mg or 0.625 mg oral capsules; once daily; Week 0-24, Week 28-52 during double-blind treatment period; Week 52-104 during open-label treatment period.

    Drug: VI-0106

  • Placebo comparator
    Placebo

    Placebo oral capsule; once daily; Week 0-52 during double-blind treatment period.

    Drug: Placebo

Interventions

  • Tacrolimus Extended-Release Capsules

    Also known as: Tacrolimus

  • DrugPlacebo

    Inactive oral capsule

06

What researchers measure

Primary outcomes

  1. Change from baseline in 6MWD (6 Minute Walk Distance) at Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percentage of subjects with a ≥1 category improvement vs baseline in WHO functional class at Week 24

    Time frame: Baseline to Week 24

  2. Time to clinical worsening defined as a composite of the following events:

    * All-cause death; * In-patient hospitalization for PAH or right-sided heart failure; * Worsening-related placement on a recipient list for heart-lung or lung transplantation; * Diminished functional capacity (decrease from baseline 6MWD of ≥15% with an absolute value of at least 22 meters and a ≥1 category worsening of WHO functional class); * Worsening-related need to initiate rescue therapy with an approved PAH therapy, or the need to increase the dose of an IV prostacyclin infusion by 10% or more.

    Time frame: Baseline to Week 52

  3. Time to clinical worsening by a restricted definition comprised of all-cause death and in-patient hospitalization for PAH or right-sided heart failure

    Time frame: Baseline to Week 52

  4. Change from baseline in 6MWD at Week 28

    Time frame: Baseline to Week 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 24 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 29, 2026
StartEst.
May 29, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Nov 30, 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07612657
Lead sponsor
VIVUS LLC
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 29, 2026 (estimated)
Primary completion
May 31, 2028 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
May 29, 2026

Study contacts

VIVUS Clinical
Contact
clinical@vivus.com
650-934-5200

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion